Skip to main content
2024 Canadian Cardiovascular Congress Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Handout
Handout
Networking
Networking
On-Demand
On-Demand
Early Career Involvement
Early Career Involvement
Back
Session Evaluation

CORONARY ARTERY DISEASE - GENERAL

MECHANICAL CIRCULATORY SUPPORT

CRITICAL CARE

EARLY CAREER INVOLVEMENT

154 - THE TOP 5 ICU TRIALS IN 2023-2024 FOR THE CLINICAL CARDIOLOGIST

Thursday, October 24, 2024
3:15 PM – 4:15 PM PT
Room: 211
Early Career Involvement
Workshop Description: In a fast-paced presentation workshop format, 5 trainees (or junior attendings in their first year of clinical practice) will be paired with 5 practicing intensivists to review the top 5 ICU trials published in the last year. Each trainee will present a brief 1.5-minute Cardiovascular Intensive Care Unit (CICU) case that highlights the potential impact of the major ICU clinical trial on CICU practice. The senior cardiac intensivists will provide a brief overview of the trial and discuss the applicability of the trial to CICU patient care. Both the junior and senior faculty will participate in the audience question and answer period.

Trials for discussion:
Pre-Oxi Study - NEJM 2024
EInhaled Amikacin to Prevent Ventilator-Associated Pneumonia (NEJM 2023)
Protection Trial - Intravenous Amino Acids for Kidney Protection NEJM 2024
Expedited transfer of out of hospital cardiac arrest: Arrest trial (Lancet 2023)
DanGer-Shock – NEJM 2024

This workshop is timely and relevant to CICU patient care given many large centers have evolved from acute coronary syndrome monitoring units and cardiac surgery post-operative units into intensive care units for critically ill cardiovascular patients. Cardiologists and cardiac surgeons in tertiary non-academic and academic centers are caring for patients with non-cardiovascular complications and multi-system organ failure.

A published statement authored by the Canadian CICU director’s group and endorsed by the CAIC advocated for ongoing critical care continuing medical education (CME) for cardiologists practicing in the CICU. A CANCARE survey identified that only 20% of tertiary non-academic CICUs and 46% of academic CICUs have available maintenance of competency for CICU practitioners. CCS feed back from the 2022 meeting had numerous calls for more ICU and cardiogenic shock contents.

The purpose of this workshop is to provide a focused and relevant overview of recent critical care advances for the cardiac specialist. We are replicating a workshop that was extremely well received at the Canadian Cardiovascular Congress (CCC) in 2022 and 2023. The session received very strong reviews though the CCC app and multiple attendees expressed the need for ongoing ICU-based CME in their clinical practice.

Learning Objectives:

At the end of this session participants will be able to:
  • implement sedation strategies that could potentially reduce intubation hypoxia;
  • evaluate whether peri-operative intravenous amino acids can reduce post-cardiac surgical acute kidney injury;
  • critically appraise whether routine inhaled prophylactic amikacin in ventilated patients should be used to reduce in the incidence of ventilator acquired pneumonia;
  • evaluate if expedited routine transport to cardiac arrest receiving centers improves outcomes for patients with a resuscitated cardiac arrest; and
  • incorporate the results of the DanGer-shock trial evaluating the role of ImpellaTM temporary mechanical circulatory support into your care of patients with cardiogenic shock.
Disclosure(s):
Sean Van Diepen, MD FRCPC: No financial relationships to disclose
Chris Brian Overgaard, MD, MSc., FRCPC: No financial relationships to disclose
Filio Billia, MD PhD FRCPC FACC: Abbottt Laboratories: physician-initiated research funding (Ongoing)
Jordan H. Hutson, MD, FRCPC, DRCPSC (Echo): No financial relationships to disclose
Justin Chow, MD, FRCPC: No financial relationships to disclose
Jordan Webber, MD, FRCPC: No financial relationships to disclose
Tiffany Yuen, MD, FRCPC: No financial relationships to disclose
Dave Nagpal, MD, FRCSC: No financial relationships to disclose
Mena Gewarges, MD: No financial relationships to disclose
Erin Rayner-Hartley, MD FRCPC: No financial relationships to disclose
Andrew Caddell, MD, MSc, FRCPC: No financial relationships to disclose
Adriana C. Luk, MD, MSc: No financial relationships to disclose
Richard Vandedriend, MD, FRCPC: Astra-Zeneca: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Bayer: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Novartis: Speaker/Honoraria (Terminated, March 20, 2024); Novo Nordisk: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
Julie Kromm: No financial relationships to disclose